Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Courtney D. DiNardo, Justin M. Watts, Eytan M. Stein, Stephane de Botton, Amir T. Fathi, Gabrielle T. Prince, Anthony S. Stein, James M. Foran, Richard M. Stone, Prapti A. Patel, Martin S. Tallman, Sung Choe, Hongfang Wang, Vickie Zhang, David Dai, Bin Fan, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Samuel V. Agresta, Hua Liu, Bin Wu, Eyal C. Attar, Hagop M. Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Massachusetts General Hospital, Johns Hopkins Hospital, City Of Hope National Medical Center, Mayo Clinic in Florida, Dana-Farber Cancer Institute, The University of Texas Southwestern Medical Center, Agios Pharmaceuticals (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2908377331